EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Real-world outcomes of ipilimumab plus nivolumab in esophageal squamous cell carcinoma: a multi-institutional large cohort study

Shuichiro Hara, Tomoki Makino, Shigeto Nakai, Kota Momose, Kotaro Yamashita, Koji Tanaka, Taro Satoh, Keijiro Sugimura, Ryohei Kawabata, Atsushi Takeno, Masaaki Motoori, Makoto Yamasaki und 5 weitere

Cancer Immunology, Immunotherapy · 14.06.2026 · 75 (9)

DOI: 10.1007/s00262-026-04451-7 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 14.06.2026. Verfasst von Shuichiro Hara und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2-E2, Yamada-Oka, Suita, Osaka, 565-0871, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Ipilimumab, Nivolumab. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaIpilimumabNivolumabAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleAgedMiddle AgedRetrospective StudiesPrognosisTreatment OutcomeAdultAged, 80 and over

Stichwörter der Autor:innen

C-reactive protein–to–albumin ratioEsophageal squamous cell carcinomaIpilimumab plus nivolumabReal-world cohortUnresectable advanced

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2-E2, Yamada-Oka, Suita, Osaka, 565-0871, Japan.
  • Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2-E2, Yamada-Oka, Suita, Osaka, 565-0871, Japan. tmakino@gesurg.med.osaka-u.ac.jp.
  • Center for Cancer Genomics and Precision Medicine, The University of Osaka Hospital, Suita, Osaka, Japan.
  • Department of Surgery, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.
  • Department of Surgery, Sakai City Medical Center, Sakai, Osaka, Japan.
  • Department of Surgery, NHO Osaka National Hospital, Osaka, Osaka, Japan.

Zitieren

APA

Hara, S., Makino, T., Nakai, S., Momose, K., Yamashita, K., Tanaka, K., Satoh, T., Sugimura, K., Kawabata, R., Takeno, A., Motoori, M., Yamasaki, M., Miyata, H., Kimura, Y., Yasuda, T., Eguchi, H., & Doki, Y. (2026). Real-world outcomes of ipilimumab plus nivolumab in esophageal squamous cell carcinoma: a multi-institutional large cohort study. Cancer Immunology, Immunotherapy, 75(9). https://doi.org/10.1007/s00262-026-04451-7

Vancouver

Hara S, Makino T, Nakai S, Momose K, Yamashita K, Tanaka K, et al. Real-world outcomes of ipilimumab plus nivolumab in esophageal squamous cell carcinoma: a multi-institutional large cohort study. Cancer Immunology, Immunotherapy. 2026;75(9). doi:10.1007/s00262-026-04451-7

BibTeX
@article{Hara2026,
  author = {Hara, Shuichiro and Makino, Tomoki and Nakai, Shigeto and Momose, Kota and Yamashita, Kotaro and Tanaka, Koji and Satoh, Taro and Sugimura, Keijiro and Kawabata, Ryohei and Takeno, Atsushi and Motoori, Masaaki and Yamasaki, Makoto and Miyata, Hiroshi and Kimura, Yutaka and Yasuda, Takushi and Eguchi, Hidetoshi and Doki, Yuichiro},
  title = {Real-world outcomes of ipilimumab plus nivolumab in esophageal squamous cell carcinoma: a multi-institutional large cohort study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {9},
  doi = {10.1007/s00262-026-04451-7}
}
Kostenlos starten →